Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients

被引:36
作者
Falagas, ME
Snydman, DR
Griffith, J
Werner, BG
Freeman, R
Rohrer, R
Fairchild, R
Fawaz, K
Hoffman, MA
Kaplan, M
Gill, M
Rubin, RH
Dienstag, JL
Doran, M
ORourke, E
Vacanti, J
Jenkins, R
Lewis, WD
Hammer, S
Martin, M
Grady, GF
Leszczynski, J
Dougherty, N
Katz, A
Fausett, G
Platt, R
Cheeseman, SH
Pasternack, M
Gorbach, SL
机构
[1] TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111
[2] TUFTS UNIV NEW ENGLAND MED CTR,DEPT PATHOL,BOSTON,MA 02111
[3] TUFTS UNIV NEW ENGLAND MED CTR,DEPT SURG,BOSTON,MA 02111
[4] TUFTS UNIV,SCH MED,BOSTON,MA 02111
[5] MASSACHUSETTS GEN HOSP,BOSTON,MA 02114
[6] CHILDRENS HOSP,BOSTON,MA 02115
[7] NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215
[8] MASSACHUSETTS STATE LAB INST,BOSTON,MA
关键词
D O I
10.1086/514555
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Predictors of recurrent cytomegalovirus (CMV) disease after the first episode of successfully treated CMV disease in orthotopic liver transplant recipients were studied. Recurrent CMV disease was defined as disease diagnosed >14 days after the end of a minimum 8-day course of ganciclovir therapy for the first episode and was classified as early or late if it occurred within or after 90 days, respectively, after completion of ganciclovir treatment, Eleven (27%) of 41 patients had recurrent CMV disease (nine early recurrences and two late recurrences). Death was more likely to occur in patients with recurrent CMV disease than in those without it (55% vs. 13%, respectively; P = .006). Initial episodes of multiorgan CMV disease (P = .001) and CMV pneumonia (P = .012) were associated with early recurrence, Multivariate analysis showed that multiorgan CMV disease was independently associated with early recurrence (P = .003; odds ratio, 13.5; 95% confidence interval, 2.4-76.8), Recognition of risk factors for recurrent CMV disease may help identify patients for whom a more intensive therapeutic or diagnostic approach is needed.
引用
收藏
页码:314 / 317
页数:4
相关论文
共 7 条
  • [1] GANCICLOVIR SUSCEPTIBILITIES OF CYTOMEGALOVIRUS (CMV) ISOLATES FROM SOLID-ORGAN TRANSPLANT RECIPIENTS WITH CMV VIREMIA AFTER ANTIVIRAL PROPHYLAXIS
    BOIVIN, G
    ERICE, A
    CRANE, DD
    DUNN, DL
    BALFOUR, HH
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (02) : 332 - 335
  • [2] TREATMENT OF INVASIVE CYTOMEGALOVIRUS DISEASE IN SOLID ORGAN TRANSPLANT PATIENTS WITH GANCICLOVIR
    DUNN, DL
    MAYORAL, JL
    GILLINGHAM, KJ
    LOEFFLER, CM
    BRAYMAN, KL
    KRAMER, MA
    ERICE, A
    BALFOUR, HH
    FLETCHER, CV
    BOLMAN, RM
    MATAS, AJ
    PAYNE, WD
    SUTHERLAND, DER
    NAJARIAN, JS
    [J]. TRANSPLANTATION, 1991, 51 (01) : 98 - 106
  • [3] FALAGAS ME, 1995, TRANSPL P, V27, P34
  • [4] HIBBERD PL, 1994, 34 INT C ANT AG CHEM, P136
  • [5] SAWYER MD, 1993, ARCH SURG-CHICAGO, V128, P165
  • [6] CYTOMEGALOVIRUS IMMUNE GLOBULIN PROPHYLAXIS IN LIVER-TRANSPLANTATION - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    SNYDMAN, DR
    WERNER, BG
    DOUGHERTY, NN
    GRIFFITH, J
    RUBIN, RH
    DIENSTAG, JL
    ROHRER, RH
    FREEMAN, R
    JENKINS, R
    LEWIS, D
    HAMMER, S
    OROURKE, E
    GRADY, GF
    FAWAZ, K
    KAPLAN, MM
    HOFFMAN, MA
    KATZ, AT
    DORAN, M
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) : 984 - 991
  • [7] STRATTA RJ, 1989, ARCH SURG-CHICAGO, V124, P1443